AI Model Could Improve Liver Transplant Outcomes
A Stanford-led team developed a machine-learning model that helps predict the time between life support removal…
It is our great honor to welcome you to the Middle East and North Africa Society for the Study of the Liver (MENASL). The establishment of this Society marks an important milestone for our region, uniting colleagues across the Middle East and North Africa under a shared vision: to advance liver health through science, collaboration, and innovation. The MENA region bears a substantial burden of liver diseases—viral hepatitis, steatotic liver disease, and hepatocellular carcinoma remain leading causes of morbidity and mortality. Yet despite the magnitude of this challenge, our region continues to be underrepresented in global research, clinical trials, and evidence synthesis. MENASL was created to bridge this gap. Our goal is to provide a strong, cohesive platform that amplifies regional expertise, strengthens research capacity, and ensures that the voices and perspectives of our clinicians and scientists are fully represented on the global stage. MENASL is designed to be more than a scientific society. It is a community—a place where researchers, clinicians, trainees, and partners come together to share knowledge, generate evidence, and build sustainable models of care that reflect our region’s realities and diversity. Through our conferences, educational programs, clinical guidelines, and research initiatives, we aim to cultivate excellence, support early-career professionals, and empower teams across the region to deliver the highest standards of care to their patients. We are committed to fostering collaboration both within the region and with leading international liver societies. By building bridges, sharing data, and nurturing partnerships, MENASL will contribute to shaping global hepatology and advancing the science that will define the future of liver disease management. We are deeply grateful to all colleagues who have joined us on this journey and who continue to contribute their expertise, time, and passion. We invite you to become an active member of MENASL, engage in our initiatives, and help us build a society that reflects the strength, resilience, and ambition of our region. Together, we can elevate liver health in the Middle East and North Africa and ensure a healthier future for generations to come.
A Stanford-led team developed a machine-learning model that helps predict the time between life support removal…
The Middle East and North Africa Society for the Study of the Liver (MENASL) is pleased to invite you to MENASL 2026, a premier scientific…
Recent summaries of hepatology advances emphasize emerging medications targeting metabolic dysfunction-associated steatotic liver disease (MASLD) and related conditions. These include agents that may reduce inflammation,…
Experts from Cedars-Sinai shared cutting-edge research at the American Association for the Study of Liver Diseases annual meeting, highlighting breakthroughs in diagnostics, treatment strategies, and…
In a Phase 2 trial, DR10624 — a first-of-its-kind agent that targets FGF21, glucagon, and GLP-1 pathways — significantly lowered triglycerides and improved liver health…




















